NASDAQ: BLUE | Healthcare / Biotechnology / USA |
3.86 | +0.0200 | +0.52% | Vol 3.36M | 1Y Perf -49.80% |
Nov 29th, 2023 16:00 DELAYED |
BID | 3.83 | ASK | 3.90 | ||
Open | 3.89 | Previous Close | 3.84 | ||
Pre-Market | 3.90 | After-Market | - | ||
0.04 1.04% | - - |
Target Price | 6.88 | Analyst Rating | Moderate Buy 2.52 | |
Potential % | 78.24 | Finscreener Ranking | ☆ 29.44 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ☆ 30.74 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ☆ 26.91 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 22.11 | Earnings Rating | Strong Buy | |
Market Cap | 422.04M | Earnings Date | 7th Nov 2023 | |
Alpha | -0.05 | Standard Deviation | 0.19 | |
Beta | 0.91 |
Today's Price Range 3.844.05 | 52W Range 2.528.58 | 5 Year PE Ratio Range -7.30-3.50 |
Summary:
Buy
Technical Indicators: | Neutral |
Moving Averages: | Strong Buy |
Performance | |||
---|---|---|---|
1 Week | 1.85% | ||
1 Month | 36.88% | ||
3 Months | 3.21% | ||
6 Months | 16.62% | ||
1 Year | -49.80% | ||
3 Years | -91.25% | ||
5 Years | -96.86% | ||
10 Years | -81.10% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -33.15 | |||
ROE last 12 Months | -101.27 | |||
ROA (5Y Avg) | -41.98 | |||
ROA last 12 Months | -54.85 | |||
ROC (5Y Avg) | -32.22 | |||
ROC last 12 Months | -61.02 | |||
Return on invested Capital Q | -16.87 | |||
Return on invested Capital Y | -20.38 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.30 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-1.30 | ||||
4.10 | ||||
176.89 | ||||
5.70 | ||||
-2.10 | ||||
-5.79 | ||||
4.25 | ||||
1.92 | ||||
790.25M | ||||
Forward PE | -2.09 | |||
PEG | -0.02 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.20 | ||||
1.30 | ||||
0.60 | ||||
1.75 | ||||
- | ||||
Leverage Ratio | 2.70 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-235.30 | ||||
-8 604.10 | ||||
-8 486.30 | ||||
-2 442.70 | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
3.53M | ||||
0.04 | ||||
-46.11 | ||||
-0.13 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2023 | -0.69 | -0.66 | 4.35 |
Q02 2023 | -0.72 | -0.67 | 6.94 |
Q01 2023 | -0.54 | 0.21 | 138.89 |
Q04 2022 | -0.45 | -0.57 | -26.67 |
Q03 2022 | -1.28 | -0.92 | 28.12 |
Q02 2022 | -1.31 | -1.29 | 1.53 |
Q01 2022 | -1.26 | -1.66 | -31.75 |
Q04 2021 | -1.82 | -1.82 | 0.00 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2023 QR | -0.63 | 19.23 | Positive |
12/2023 FY | -1.83 | 10.29 | Positive |
3/2024 QR | -0.35 | 40.68 | Positive |
12/2024 FY | -1.86 | 7.00 | Positive |
Next Report Date | - |
Estimated EPS Next Report | -0.69 |
Estimates Count | 8 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 3.36M |
Shares Outstanding | 109.34K |
Shares Float | 107.04M |
Trades Count | 19.16K |
Dollar Volume | 13.12M |
Avg. Volume | 3.57M |
Avg. Weekly Volume | 3.26M |
Avg. Monthly Volume | 4.03M |
Avg. Quarterly Volume | 3.42M |
bluebird bio Inc. (NASDAQ: BLUE) stock closed at 3.86 per share at the end of the most recent trading day (a 0.52% change compared to the prior day closing price) with a volume of 3.36M shares and market capitalization of 422.04M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1213 people. bluebird bio Inc. CEO is Nick Leschly.
The one-year performance of bluebird bio Inc. stock is -49.8%, while year-to-date (YTD) performance is -44.22%. BLUE stock has a five-year performance of -96.86%. Its 52-week range is between 2.52 and 8.58, which gives BLUE stock a 52-week price range ratio of 22.11%
bluebird bio Inc. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 4.10, a price-to-sale (PS) ratio of 176.89, a price to cashflow ratio of 5.70, a PEG ratio of -0.02, a ROA of -54.85%, a ROC of -61.02% and a ROE of -101.27%. The company’s profit margin is -%, its EBITDA margin is -8 486.30%, and its revenue ttm is $3.53 Million , which makes it $0.04 revenue per share.
Of the last four earnings reports from bluebird bio Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.69 for the next earnings report. bluebird bio Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for bluebird bio Inc. is Moderate Buy (2.52), with a target price of $6.88, which is +78.24% compared to the current price. The earnings rating for bluebird bio Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
bluebird bio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
bluebird bio Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 22.27, ATR14 : 0.29, CCI20 : 119.54, Chaikin Money Flow : 0.05, MACD : 0.22, Money Flow Index : 42.80, ROC : 27.18, RSI : 62.13, STOCH (14,3) : 79.23, STOCH RSI : 0.64, UO : 52.38, Williams %R : -20.77), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of bluebird bio Inc. in the last 12-months were: Andrew Obenshain (Sold 3 178 shares of value $24 802 ), Colvin Richard A. (Sold 557 shares of value $4 345 ), Klima Thomas (Sold 4 130 shares of value $14 455 ), Leschly Nick (Sold 4 290 shares of value $33 462 ), Nick Leschly (Sold 4 290 shares of value $33 480 ), Obenshain Andrew (Sold 3 178 shares of value $24 788 ), Richard A. Colvin (Sold 557 shares of value $4 347 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.
CEO: Nick Leschly
Telephone: +1 339 499-9300
Address: 60 Binney Street, Cambridge 02142, MA, US
Number of employees: 1 213
Sun, 13 Aug 2023 01:46 GMT Bluebird Bio (BLUE) Receives a Hold from RBC Capital
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.